Biosimilars Portfolio

Biosimilars Portfolio
Product Description

  • Pegfilgrastim (Filed with EMA)
  • Filgrastim (Filed with EMA)
  • Trastuzumab (Filed with EMA, MHRA, Received recommendation for marketing authorization in India)
  • Bevacizumab (Filed with MHRA)
  • Omalizumab (Global PhIII ongoing)
  • Denosumab (Global PhIII ongoing)
  • Ranibizumab (Global PhIII ongoing)
  • Tocilizumab (PhIII ongoing)
  • Ustekinumab (PhI complete)

Read more Show less

CuraTeQ Biologics

  • IN
  • 2024
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Generics/Biosimilars Manufacturer
Primary activities
Biopharmaceutical
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile
Categories
more categories Show less

CuraTeQ Biologics

  • IN
  • 2024
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Generics/Biosimilars Manufacturer
Primary activities
Biopharmaceutical
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile

More Products from CuraTeQ Biologics (1)

  • Synthetic Peptide APIs Portfolio

    Product Synthetic Peptide APIs Portfolio

    • Vasopressin (US DMF Approved) • Icatibant acetate (US DMF Approved) • Leuprolide acetate (US DMF Approved) • Linaclotide (US DMF Approved) • Etelcalcetide (US DMF Approved) • Desmopressin (US DMF Approved) • Calcitonin salmon (US DMF Filed) • Ganirelix acetate (US DMF Filed) • Degarelix (US DMF ...

CuraTeQ Biologics resources (1)